
What is claimed is:

1. A compound of formula (I)




(I)


or a pharmaceutically acceptable salt thereof, wherein:

R^7 is a peptide;


R^8 is selected from the group consisting of:



,




, and




,


Q is selected from the group consisting of




,




,




,




,


R9
R10
R6
R5
Aryl or
Hetaryl
[N,O,S]
O
R4
R3
S
S
O
R1
R2
R11
R12


,


R1
R2
R6
R5
Aryl or
Hetaryl
S
S
R3
R4


,


R9
R10
R6
R5
Aryl or
Hetaryl
O
N
H
[AA]x
H
N
O
O
R1
R2
S
S
R4
R3
R11
R12


,


R9
R10
R6
R5
Aryl or
Hetaryl
O
N
H
[AA]x
H
N
O
O
R1
R2
S
S
O
R4
R3
R11
R12


,


O
[AA]x
H
N
O
O
R1
R2
S
S
R4
R3


,


R2
S
R1
S
R5
R6
O
R3
[N,O]
R4
O
O
Aryl or
Hetaryl
R9
R12
R10
R11


,



R2
S
R1
S
O
R5
R6
O
R3
[C,N,O]
[N,O]
R4
O
Aryl or
Hetaryl
R9
R12
R10
R11


,



R1
R2
S
S
O
Aryl or
Hetaryl
R9
R12
R10
R11


,


O
R1
R2
[C,N,O]
S
S
Aryl or
Hetaryl
R9
R12
R10
R11
,



[N,O]
S
S
O
Aryl or
Hetaryl
R9
R12
R10
R11
,



R1
R2
S
[N,O]
S
O
Aryl or
Hetaryl
R9
R12
R10
R11
,


O
R5
R6
R9
O
R3
R4
S
S
O
[N,O]
R1
R2
R10
O
R11
S1
,



O
R5
R6
R9
H
N
R3
R4
R1
R2
S
S
O
O
R10
O
R11
S1

,



O
R5
R6
R9
H
N
R3
R4
S
S
O
R1
R2
R10
O
R11
S1


O
R5
R6
R9
R1
R2
O
S
S
O
R3
R4
R10
O
R11
S1


,


R5
R6
O
R4
R3
P
S
S
O
O
[N,O]
R13
R1
R2


,


R5
R6
O
P
O
O
[N,O]
R13
R1
R2
Aryl or
Hetaryl
S
S
R3
R4


,


R5
R6
O
P
O
O
O
R9
R10
Aryl or
Hetaryl
[N,O,S]
O
O
R4
R3
S
S
R1
R2
R11
R12


,


O
P
O
[N,O]
R13
R4
R3
S
S
R1
R2

,


O
P
O
[N,O]
R13
R1
R2
Aryl or
Hetaryl
S
S
R3
R4

, and



;

R^1, R^2, R^3, R^4, R^5, R^6, R^9, R^{10}, R^{11}, and R^{12} are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, 5-10 membered heteroaryl, halo, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$, wherein said C_{1-4} alkyl, C_{1-4} alkenyl, C_{6-10} aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or R^1 and R^2 together with the carbon atom to which they are attached form a C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;


or R^1 and R^3 together with the carbon atom to which they are attached form a C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or R^3 and R^4 together with the carbon atom to which they are attached form an C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or R^5 and R^6 together with the carbon atom to which they are attached form an C_{3-7} cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO_2, OR^{a1}, SR^{a1}, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

R^{13} is H or C_{1-6} alkyl;

A is H or C_{1-4} alkyl;



is C_{6-10} aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;


[N, O, S] is NH, O, or S;

[N, O] is NH or O;

[C, N, O] is CR^XR^Y, NH, or O;

each R^X and R^Y is independently selected from H and C_{1-4} alkyl;

$[AA]_X$ is a peptide that may be cleaved by enzymatic action;

S1 is 

;

each R^a, R^b, R^c, and R^d is independently selected from H, C_{1-4} alkyl, OR^{a2}, CO_2R^{a2}, and $OC(=O)R^{a2}$, wherein said C_{1-4} alkyl is optionally substituted with OR^{a2}, CO_2R^{a2}, and $OC(=O)R^{a2}$;

R^{a1}, R^{b1}, R^{c1}, and R^{d1} are each independently selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OH, CN, NO_2, and CO_2CH_3; wherein said C_{1-6} alkyl and C_{2-6} alkenyl are each optionally substituted with OH, CN, NO_2, or CO_2CH_3;

R^{a2} is H or C_{1-4} alkyl; and

n is 0 or 1.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide capable of selectively delivering R^8Q- across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1);

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2);

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3);

Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4); and

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5);

and wherein R^7 is attached to Q through a cysteine residue of R^7.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1),

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2), and

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3),

and wherein R^7 is attached to Q through a cysteine residue of R^7.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising the sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1).

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising the sequence:

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2).

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising the sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3).

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising the sequence:

Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4).

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 is a peptide comprising the sequence:
AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5).

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each independently selected from H and methyl, and R^3, R^4, R^5, and R^6 are each H.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each independently selected from H and methyl.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each H.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are each H.


14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are each H.

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^9, R^{10}, R^{11}, and R^{12} are each independently selected from H and methyl.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the enzyme capable of cleaving $[AA]_X$ is Cathepsin B, MMPXX, DPPIV, glycoprotein, peptidase, or caspase.


17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein [AA]x is a peptide having two to ten amino acid residues.

18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein S1 is a group having the following structure:




19. A pharmaceutical composition that comprises a compound of claim 1, or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R8 is:




21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is:



22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are each independently selected from H and methyl.

23. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are each H.

24. A compound, which is:




,

or a pharmaceutically acceptable salt thereof; wherein Pv1 is a peptide comprising the following sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

25. A compound, which is:




,

or a pharmaceutically acceptable salt thereof; wherein Pv1 is a peptide comprising the following sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

26. A compound, which is:



or a pharmaceutically acceptable salt thereof; wherein Pv2 is a peptide comprising the following sequence:

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2).

27. A pharmaceutical composition comprising a compound of claim 24, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising a compound of claim 25, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising a compound of claim 26, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.